| Objective To explore the diagnostic values of serum tumor markers tested by chemoiluminescence combined with serum proteomic patterns by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry(SELDI-TOF-MS) technology in patients with non-small cell lung cancer.Methods Serum samples of 69 lung adenocarcinoma patients and 71 healthy controls were detected by immunoluminescence to analyze the levels of CEA, and serum samples of 59 lung squamous cellcarcinoma patients and 60 healthy controls were detected by electrochemiluminescence to analyze the levels of CYFRA21-1, while all the samples were tested by SELDI-TOF-MS with CM10-chips to analyse the differential expressions of proteomes in serum, followed by Biomarker Wizard software analysis. According to clinical pathological materials, the joint diagnostic values of two methods were evaluated. Results The sensitivity and specificity of CEA detection were 62.319%(43/69)and 92.958%(66/71) for lung adenocarcinoma,while SELDI-TOF-MS technology were 88.406 %(61/69)and 68.182%(15/22) respectively.Meanwhile, the sensitivity and specificity of combined detections of two methods were 82.609%(57/69) and 92.958%(66/71)respectively. The sensitivity and specificity of CYFRA21-1 detection were 77.966%(46/59)and 96.667%(58/60)for lung squamous cell carcinoma,while SELDI-TOF-MS technology were 83.051 %(49/59) and 65.385%(17/26). And the sensitivity and specificity of combined detections of two methods were 94.915%(56/59) and 95.000%(57/60)respectively.Conclusion The sensitivity of immunoluminescence for CEA detection together with the SELDI-TOF-MS technology was higher than the immunoluminescence for CEA detection alone in the diagnosis of lung adenocarcinoma,but it was not higher than that by SELDI-TOF-MS technology. The sensitivity of electrochemiluminescence for CYFRA21-1 detection together with the SELDI-TOF-MS technology was higher than that of the electrochemiluminescence for CYFRA21-1 detection and SELDI-TOF-MS technology alone in the diagnosis of lung squamous cell carcinoma. |
PDF Full Text Request